Targeting the secreted RGDKGE collagen fragment reduces PD‑L1 by a proteasome‑dependent mechanism and inhibits tumor growth
- Authors:
- Jennifer M. Caron
- Xianghua Han
- Christine W. Lary
- Pradeep Sathyanarayana
- Scot C. Remick
- Marc S. Ernstoff
- Meenhard Herlyn
- Peter C. Brooks
-
Affiliations: MaineHealth Institute for Research, Center for Molecular Medicine, Scarborough, ME 04074, USA, Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD 20892, USA, Wistar Institute, Philadelphia, PA 19104, USA - Published online on: January 12, 2023 https://doi.org/10.3892/or.2023.8481
- Article Number: 44
-
Copyright: © Caron et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Brassart-Pasco S, Brezillon S, Brassart B, Ramont L, Oudart JB and Monboisse JC: Tumor microenvironment: Extracellular matrix alterations influence tumor progression. Front Oncol. 10:3972020. View Article : Google Scholar : PubMed/NCBI | |
Ruiter D, Bogenrieder T, Elder D and Herlyn M: Melanoma-stroma interactions: Structural and functional aspects. Lancet Oncol. 3:35–43. 2002. View Article : Google Scholar : PubMed/NCBI | |
Han X, Caron JM and Brooks PC: Cryptic collagen elements as signaling hubs in the regulation of tumor growth and metastasis. J Cell Physiol. 235:9005–9020. 2020. View Article : Google Scholar : PubMed/NCBI | |
Contois L, Akalu A and Brooks PC: Integrins as ‘functional hubs’ in the regulation of pathological angiogenesis. Semin Cancer Biol. 19:318–328. 2009. View Article : Google Scholar : PubMed/NCBI | |
Ricard-Blum S: The collagen family. Cold Spring Harb Perspect Biol. 3:a0049782011. View Article : Google Scholar : PubMed/NCBI | |
Zeltz C and Gullberg D: The integrin-collagen connection-a glue for tissue repair? J Cell Sci. 129:12842016. View Article : Google Scholar : PubMed/NCBI | |
Leitinger B: Transmembrane collagen receptors. Annu Rev Cell Dev Biol. 27:265–290. 2011. View Article : Google Scholar : PubMed/NCBI | |
Bienkowski RS, Curran SF and Berg RA: Kinetics of intracellular degradation of newly synthesized collagen. Biochemistry. 25:2455–2459. 1986. View Article : Google Scholar : PubMed/NCBI | |
Ames JJ, Contois L, Caron JM, Tweedie E, Yang X, Friesel R, Vary C and Brooks PC: Identification of an endogenously generated cryptic collagen epitope (XL313) that may selectively regulate angiogenesis by an integrin yes-associated protein (YAP) mechano-transduction pathway. J Biol Chem. 291:2731–2750. 2016. View Article : Google Scholar : PubMed/NCBI | |
Han X, Caron JM, Lary CW, Sathyanarayana P, Vary C and Brooks PC: An RGDKGE-containing cryptic collagen fragment regulates phosphorylation of large tumor suppressor kinase-1 and controls ovarian tumor growth by a YAP-associated protein-dependent mechanism. Am J Pathol. 191:527–544. 2021. View Article : Google Scholar : PubMed/NCBI | |
Kim MH, Kim CG, Kim SK, Shin SJ, Choe EA, Park SH, Shin EC and Kim J: YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma. Cancer Immunol Res. 6:255–266. 2018. View Article : Google Scholar : PubMed/NCBI | |
Hsu PC, Miao J, Wang YC, Zhang WQ, Yang YL, Wang CW, Yang CT, Huang Z, You J, Xu Z, et al: Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma. J Cell Mol Med. 22:3139–3148. 2018. View Article : Google Scholar : PubMed/NCBI | |
Lee BS, Park DI, Lee DH, Lee JE, Yeo MK, Park YH, Lim DS, Choi W, Lee DH, Yoo G, et al: Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. Biochem Biophy Res Commun. 491:493–499. 2017. View Article : Google Scholar : PubMed/NCBI | |
Jensen C, Madsen DH, Hansen M, Schmidt H, Svane IM, Karsdal MA and Willumsen N: Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients. J Immunother Cancer. 6:1522018. View Article : Google Scholar : PubMed/NCBI | |
Hurkmans DP, Jensen C, Koolen SLW, Aerts J, Karsdal MA, Mathijssen RHJ and Willumsen N: Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma. J Immunother Cancer. 8:e0011932020. View Article : Google Scholar : PubMed/NCBI | |
Abdou Y, Pandey M, Sarma M, Shah S, Baron J and Ernstoff MS: Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. Br J Clin Pharmacol. 86:1690–1702. 2020. View Article : Google Scholar : PubMed/NCBI | |
Gandhi S, Pandey MR, Attwood K, Ji W, Witkiewicz AK, Knudsen ES, Allen C, Tario JD, Wallace PK, Cedeno CD, et al: Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: Safety, tolerability, and preliminary evidence of antitumor activity. Clin Cancer Res. 27:87–95. 2021. View Article : Google Scholar : PubMed/NCBI | |
Somasundaram R, Connelly T, Choi R, Choi H, Samarkina A, Li L, Gregorio E, Chen Y, Thakur R, Abdel-Mohsen M, et al: Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nat Commun. 12:3462021. View Article : Google Scholar : PubMed/NCBI | |
Cha JH, Chan LC, Li CW, Hsu JL and Hung MC: Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 76:359–370. 2019. View Article : Google Scholar : PubMed/NCBI | |
Sun C, Mezzadra R and Schumacher TN: Regulation and function of the PD-L1 checkpoint. Immunity. 48:434–452. 2018. View Article : Google Scholar : PubMed/NCBI | |
Gou Q, Dong C, Xu H, Khan B, Jin J, Liu Q, Shi J and Hou Y: PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis. 11:9552020. View Article : Google Scholar : PubMed/NCBI | |
Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, et al: Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 7:126322016. View Article : Google Scholar : PubMed/NCBI | |
Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, et al: Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell. 71:606–620.e7. 2018. View Article : Google Scholar : PubMed/NCBI | |
Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, et al: CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 549:101–105. 2017. View Article : Google Scholar : PubMed/NCBI | |
Wang H, Yao H, Li C, Shi H, Lan J, Li Z, Zhang Y, Liang L, Fang JY and Xu J: HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nat Chem Biol. 15:42–50. 2019. View Article : Google Scholar : PubMed/NCBI | |
Coelho MA, de Carné Trécesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, East P, Spencer-Dene B, Nye E, Barnouin K, et al: Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity. 47:1083–1099.e6. 2017. View Article : Google Scholar : PubMed/NCBI | |
Lin HY, Chin YT, Nana AW, Shih YJ, Lai HY, Tang HY, Leinung M, Mousa SA and Davis PJ: Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells. Steroids. 114:59–67. 2016. View Article : Google Scholar : PubMed/NCBI | |
Ren D, Zhao J, Sun Y, Li D, Meng Z, Wang B, Fan P, Liu Z, Jin X and Wu H: Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway. J Exp Clin Cancer Res. 38:4852019. View Article : Google Scholar : PubMed/NCBI | |
Vannini A, Leoni V, Barboni C, Sanapo M, Zaghini A, Malatesta P, Campadelli-Fiume G and Gianni T: αvβ3-integrin regulates PD-L1 expression and is involved in cancer immune evasion. Proc Natl Acad Sci USA. 116:20141–20150. 2019. View Article : Google Scholar : PubMed/NCBI | |
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI | |
Caron JM, Han X, Contois L, Vary CPH and Brooks PC: The HU177 collagen epitope controls melanoma cell migration and experimental metastasis by a CDK5/YAP-dependent mechanism. Am J Pathol. 188:2356–2368. 2018. View Article : Google Scholar : PubMed/NCBI | |
Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White JG and Keely PJ: Collagen density promotes mammary tumor initiation and progression. BMC Med. 6:112008. View Article : Google Scholar : PubMed/NCBI | |
Vellinga TT, den Uil S, Rinkes IH, Marvin D, Ponsioen B, Alvarez-Varela A, Fatrai S, Scheele C, Zwijnenburg DA, Snippert H, et al: Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion. Oncogene. 35:5263–5271. 2016. View Article : Google Scholar : PubMed/NCBI | |
van Kempen LC, Rijntjes J, Mamor-Cornelissen I, Vincent-Naulleau S, Gerritsen MJ, Ruiter DJ, van Dijk MC, Geffrotin C and van Muijen GN: Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma. Int J Cancer. 122:1019–1029. 2008. View Article : Google Scholar : PubMed/NCBI | |
Noel A, Munaut C, Boulvain A, Calberg-Bacq CM, Lambert CA, Nusgens B, Lapiere CM and Foidart JM: Modulation of collagen and fibronectin synthesis in fibroblasts by normal and malignant cells. J Cell Biochem. 48:150–161. 1992. View Article : Google Scholar : PubMed/NCBI | |
Afik R, Zigmond E, Vugman M, Klepfish M, Shimshoni E, Pasmanik-Chor M, Shenoy A, Bassat E, Halpern Z, Geiger T, et al: Tumor macrophages are pivotal constructors of tumor collagenous matrix. J Exp Med. 213:2315–2331. 2016. View Article : Google Scholar : PubMed/NCBI | |
Gupta HB, Clark CA, Yuan B, Sareddy G, Pandweswara S, Padron AS, Hurez V, Conejo-Garcia J, Vadlamudi R, Li R and Curiel TJ: Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. Signal Transduct Target Ther. 1:160302016. View Article : Google Scholar : PubMed/NCBI | |
Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K, et al: Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 76:6964–6974. 2016. View Article : Google Scholar : PubMed/NCBI | |
Hudson K, Cross N, Jordan-Mahy N and Leyland R: The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: Implications for immunotherapy treatment. Front Immunol. 11:5689312020. View Article : Google Scholar : PubMed/NCBI | |
Xue Z, Zheng S, Linghu D, Liu B, Yang Y, Chen MK, Huang H, Song J, Li H, Wang J, et al: PD-L1 deficiency sensitizes tumor cells to DNA-PK inhibition and enhances cGAS-STING activation. Am J Cancer Res. 12:2363–2375. 2022.PubMed/NCBI | |
VerPlank JJS, Lokireddy S, Zhao J and Goldberg AL: 26S Proteasomes are rapidly activated by diverse hormones and physiological states that raise cAMP and cause Rpn6 phosphorylation. Proc Natl Acd Sci USA. 116:4228–4237. 2019. View Article : Google Scholar : PubMed/NCBI | |
Asai M, Tsukamoto O, Minamino T, Asanuma H, Fujita M, Asano Y, Takahama H, Sasaki H, Higo S, Asakura M, et al: PKA rapidly enhances proteasome assembly and activity in in vivo canine hearts. J Mol Cell Cardiol. 46:452–462. 2009. View Article : Google Scholar : PubMed/NCBI | |
Lokireddy S, Kukushkin NV and Goldberg AL: cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. Proc Natl Acad Sci USA. 112:E7176–E7185. 2015. View Article : Google Scholar : PubMed/NCBI | |
Qin XY, Zhang YL, Chi YF, Yan B, Zeng XJ, Li HH and Liu Y: Angiotensin II regulates Th1 T cell differentiation through angiotensin II type 1 receptor-PKA-mediated activation of proteasome. Cell Physiol Biochem. 45:1366–1376. 2018. View Article : Google Scholar : PubMed/NCBI | |
Kim S, Harris M and Varner JA: Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A. J Biol Chem. 275:33920–33928. 2000. View Article : Google Scholar : PubMed/NCBI | |
Whelan MC and Senger DR: Collagen I initiates endothelial cell morphogenesis by inducing actin polymerization through suppression of cyclic AMP and protein kinase A. J Biol Chem. 278:327–334. 2003. View Article : Google Scholar : PubMed/NCBI | |
Kim M, Kim M, Lee S, Kuninaka S, Saya H, Lee H, Lee S and Lim DS: cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes. EMBO J. 32:1543–1555. 2013. View Article : Google Scholar : PubMed/NCBI | |
Yu FX, Zhang Y, Park HW, Jewell JL, Chen Q, Deng Y, Pan D, Taylor SS, Lai ZC and Guan KL: Protein kinase A activates the hippo pathway to modulate cell proliferation and differentiation. Genes Devel. 27:1223–1232. 2013. View Article : Google Scholar : PubMed/NCBI | |
Brooks PC, Clark RA and Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 264:569–571. 1994. View Article : Google Scholar : PubMed/NCBI | |
Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G and Cheresh DA: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1157–1164. 1994. View Article : Google Scholar : PubMed/NCBI | |
Delbaldo C, Raymond E, Vera K, Hammershaimb L, Kaucic K, Lozahic S, Marty M and Faivre S: Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphαvβeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs. 26:35–43. 2008. View Article : Google Scholar : PubMed/NCBI | |
Hersey P, Sosman J, O'Day S, Richards J, Bedikian A, Gonzalez R, Sharfman W, Weber R, Logan T, Buzoianu M, et al: A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or -dacarbazine in patients with stage IV metastatic melanoma. Cancer. 116:1526–1534. 2010. View Article : Google Scholar : PubMed/NCBI | |
Petitclerc E, Strömblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM, Cheresh DA and Brooks PC: Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. 59:2724–2730. 1999.PubMed/NCBI | |
Natali PG, Hamby CV, Felding-Habermann B, Liang B, Nicotra MR, Di Filippo F, Giannarelli D, Temponi M and Ferrone S: Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res. 57:1554–1560. 1997.PubMed/NCBI | |
Kanamori M, Vanden Berg SR, Bergers G, Berger MS and Pieper RO: Integrin beta3 overexpression suppresses tumor growth in a human model of gliomagenesis: Implications for the role of beta3 overexpression in glioblastoma multiforme. Cancer Res. 64:2751–2758. 2004. View Article : Google Scholar : PubMed/NCBI | |
Jinushi M, Chiba S, Baghdadi M, Kinoshita I, Dosaka-Akita H, Ito K, Yoshiyama H, Yagita H, Uede T and Takaoka A: ATM-mediated DNA damage signals mediate immune escape through integrin-αvβ3-dependent mechanisms. Cancer Res. 72:56–65. 2012. View Article : Google Scholar : PubMed/NCBI | |
Su X, Esser AK, Amend SR, Xiang J, Xu Y, Ross MH, Fox GC, Kobayashi T, Steri V, Roomp K, et al: Antagonizing integrin β3 increases immunosuppression in cancer. Cancer Res. 76:3484–3495. 2016. View Article : Google Scholar : PubMed/NCBI | |
Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, Sheppard D, Hynes RO and Hodivala-Dilke KM: Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nature Med. 8:27–34. 2002. View Article : Google Scholar : PubMed/NCBI | |
Xi G, Guo W, Kang D, Ma J, Fu F, Qiu L, Zheng L, He J, Fang N, Chen J, et al: Large-scale tumor-associated collagen signatures identify high-risk breast cancer patients. Theranostics. 11:3229–3243. 2021. View Article : Google Scholar : PubMed/NCBI | |
Drifka CR, Loeffler AG, Mathewson K, Keikhosravi A, Eickhoff JC, Liu Y, Weber SM, Kao WJ and Eliceiri KW: Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection. Oncotarget. 7:76197–76213. 2016. View Article : Google Scholar : PubMed/NCBI | |
Wu PC, Hsieh TY, Tsai ZU and Liu TM: In vivo quantification of the structural changes of collagens in a melanoma microenvironment with second and third harmonic generation microscopy. Sci Rep. 5:88792015. View Article : Google Scholar : PubMed/NCBI | |
Birk JW, Tadros M, Moezardalan K, Nadyarnykh O, Forouhar F, Anderson J and Campagnola P: Second harmonic generation imaging distinguishes both high-grade dysplasia and cancer from normal colonic mucosa. Dig Dis Sci. 59:1529–1534. 2014. View Article : Google Scholar : PubMed/NCBI | |
Burke K, Smid M, Dawes RP, Timmermans MA, Salzman P, van Deurzen CH, Beer DG, Foekens JA and Brown E: Using second harmonic generation to predict patient outcome in solid tumors. BMC Cancer. 15:9292015. View Article : Google Scholar : PubMed/NCBI | |
Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, Davis GE and Brooks PC: Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol. 154:1069–1079. 2001. View Article : Google Scholar : PubMed/NCBI | |
Willumsen N, Ali SM, Leitzel K, Drabick JJ, Yee N, Polimera HV, Nagabhairu V, Krecko L, Ali A, Maddukuri A, et al: Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer. Sci Rep. 9:197612019. View Article : Google Scholar : PubMed/NCBI | |
Kehlet SN, Sanz-Pamplona R, Brix S, Leeming DJ, Karsdal MA and Moreno V: Excessive collagen turnover products are released during colorectal cancer progression and elevated in serum from metastatic colorectal cancer patients. Sci Rep. 6:305992016. View Article : Google Scholar : PubMed/NCBI | |
Lipton A, Leitzel K, Ali SM, Polimera HV, Nagabhairu V, Marks E, Richardson AE, Krecko L, Ali A, Koestler W, et al: High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts. Int J Cancer. 143:3027–3034. 2018. View Article : Google Scholar : PubMed/NCBI | |
Hamilton HK, Rose AE, Christos PJ, Shapiro RL, Berman RS, Mazumdar M, Ma MW, Krich D, Liebes L, Brooks PC and Osman I: Increased shedding of HU177 correlates with worse prognosis in primary melanoma. J Transl Med. 8:192010. View Article : Google Scholar : PubMed/NCBI | |
Lindsey ML, Iyer RP, Zamilpa R, Yabluchanskiy A, DeLeon-Pennell KY, Hall ME, Kaplan A, Zouein FA, Bratton D, Flynn ER, et al: A novel collagen matricryptin reduces left ventricular dilation post-myocardial infarction by promoting scar formation and angiogenesis. J Am Coll Cardiol. 66:1364–1374. 2015. View Article : Google Scholar : PubMed/NCBI | |
Wang J and Pan W: The biological role of the collagen alpha-3 (VI) chain and its cleaved C5 domain fragment endotrophin in cancer. Onco Targets Ther. 13:5779–5793. 2020. View Article : Google Scholar : PubMed/NCBI | |
Jang JW, Kim MK and Bae SC: Reciprocal regulation of YAP/TAZ by the hippo pathway and the small GTPase pathway. Small GTPases. 11:280–288. 2020. View Article : Google Scholar : PubMed/NCBI | |
Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino G, Sodhi A, et al: Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 25:831–845. 2014. View Article : Google Scholar : PubMed/NCBI | |
Qiao Y, Chen J, Lim YB, Finch-Edmondson ML, Seshachalam VP, Qin L, Jiang T, Low BC, Singh H, Lim CT and Sudol M: YAP regulates actin dynamics through ARHGAP29 and promotes metastasis. Cell Rep. 19:1495–1502. 2017. View Article : Google Scholar : PubMed/NCBI | |
Kornepati AVR, Boyd JT, Murray CE, Saifetiarova J, de la Peña Avalos B, Rogers CM, Bai H, Padron AS, Liao Y, Ontiveros C, et al: Tumor intrinsic PD-L1 promotes DNA repair in distinct cancers and suppresses PARP inhibitor-induced synthetic lethality. Cancer Res. 82:2156–2170. 2022. View Article : Google Scholar : PubMed/NCBI | |
Lee JJ, Kim SY, Kim SH, Choi S, Lee B and Shin JS: STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells. Cell Death Dis. 13:7912022. View Article : Google Scholar : PubMed/NCBI | |
Yu J, Qin B, Moyer AM, Nowsheen S, Tu X, Dong H, Boughey JC, Goetz MP, Weinshilboum R, Lou Z and Wang L: Regulation of sister chromatid cohesion by nuclear PD-L1. Cell Res. 30:590–601. 2020. View Article : Google Scholar : PubMed/NCBI | |
Ghebeh H, Lehe C, Barhoush E, Al-Romaih K, Tulbah A, Al-Alwan M, Hendrayani SF, Manogaran P, Alaiya A, Al-Tweigeri T, et al: Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: Role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res. 12:R482010. View Article : Google Scholar : PubMed/NCBI | |
Ye L, Zhu Z, Chen X, Zhang H, Huang J, Gu S and Zhao X: The importance of exosomal PD-L1 in cancer progression and its potential as a therapeutic target. Cells. 10:32472021. View Article : Google Scholar : PubMed/NCBI | |
Gao Y, Nihira NT, Bu X, Chu C, Zhang J, Kolodziejczyk A, Fan Y, Chan NT, Ma L, Liu J, et al: Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 22:1064–1075. 2020. View Article : Google Scholar : PubMed/NCBI | |
Gao Y, Bi D, Xie R, Li M, Gau J, Liu H, Guo X, Fang J, Ding T, Zhu H, et al: Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer. Signal Transduct Target Ther. 6:3982021. View Article : Google Scholar : PubMed/NCBI | |
Wei Y, Tang X, Ren Y, Yang Y, Song F, Fu J, Liu S, Yi M, Chen J, Wang S, et al: An RNA-RNA crosstalk network involving HMGΒ1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity. Signal Transduct Target Ther. 6:4212021. View Article : Google Scholar : PubMed/NCBI | |
Zhang JJ, Zhang QS, Li ZQ, Zhou JW and Du J: Metformin attenuates PD-L1 expression through activating hippo signaling pathway in colorectal cancer cells. Am J Transl Res. 11:6965–6976. 2019.PubMed/NCBI | |
Moya IM, Castaldo SA, Van den Mooter L, Soheily S, Sansores-Garcia L, Jacobs J, Mannaerts I, Xie J, Verboven E, Hillen H, et al: Peritumoral activation of the hippo pathway effectors YAP and TAZ suppresses liver cancer in mice. Science. 366:1029–1034. 2019. View Article : Google Scholar : PubMed/NCBI | |
Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, Gangeswaran R, Manson-Bishop C, Smith P, Danovi SA, et al: Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ. 15:1752–1759. 2008. View Article : Google Scholar : PubMed/NCBI | |
Lebid A, Chung L, Pardoll DM and Pan F: YAP attenuates CD8 T cell-mediated anti-tumor response. Front Immunol. 11:5802020. View Article : Google Scholar : PubMed/NCBI | |
Stampouloglou E, Cheng N, Federico A, Slaby E, Monti S, Szeto GL and Varelas X: Yap suppresses T-cell function and infiltration in the tumor microenvironment. PLoS Biol. 18:e30005912020. View Article : Google Scholar : PubMed/NCBI | |
Ni X, Tao J, Barbi J, Chen Q, Park BV, Li Z, Zhang N, Lebid A, Ramaswamy A, Wei P, et al: YAP is essential for Treg-mediated suppression of antitumor immunity. Cancer Discov. 8:1026–1043. 2018. View Article : Google Scholar : PubMed/NCBI | |
Yang W, Yang S, Zhang F, Cheng F, Wang X and Rao J: Influence of the Hippo-YAP signalling pathway on tumor associated macrophages (TAMs) and its implications on cancer immunosuppressive microenvironment. Ann Transl Med. 8:3992020. View Article : Google Scholar : PubMed/NCBI | |
Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, Fang Z, Zhao K, Konaparthi R, Hua S, et al: Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov. 6:80–95. 2016. View Article : Google Scholar : PubMed/NCBI | |
Shibata M, Ham K and Hoque MO: A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy. Int J Cancer. 143:2133–2144. 2018. View Article : Google Scholar : PubMed/NCBI | |
Lee JY, Dominguez AA, Nam S, Stowers RS, Qi LS and Chaudhuri O: Identification of cell context-dependent YAP-associated proteins reveals β1 and β4 integrin mediate YAP translocation independently of cell spreading. Sci Rep. 9:171882019. View Article : Google Scholar : PubMed/NCBI | |
Lecker SH, Goldberg AL and Mitch WE: Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol. 17:1807–1819. 2006. View Article : Google Scholar : PubMed/NCBI | |
Bao W, Thullberg M, Zhang H, Onischenko A and Strömblad S: Cell attachment to the extracellular matrix induces proteasomal degradation of p21(CIP1) via Cdc42/Rac1 signaling. Mol Cell Biol. 22:4587–4597. 2002. View Article : Google Scholar : PubMed/NCBI | |
Sasada M, Iyoda T, Asayama T, Suenaga Y, Sakai S, Kase N, Kodama H, Yokoi S, Isohama Y and Fukai F: Inactivation of beta1 integrin induces proteasomal degradation of Myc oncoproteins. Oncotarget. 10:4960–4972. 2019. View Article : Google Scholar : PubMed/NCBI | |
Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA and Fearon DT: Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 330:827–830. 2010. View Article : Google Scholar : PubMed/NCBI | |
Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, et al: Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 25:719–734. 2014. View Article : Google Scholar : PubMed/NCBI | |
Legler DF, Johnson-Léger C, Wiedle G, Bron C and Imhof BA: The alpha v beta 3 integrin as a tumor homing ligand for lymphocytes. Eur J Immunol. 34:1608–1616. 2004. View Article : Google Scholar : PubMed/NCBI | |
Larochelle C, Uphaus T, Broux B, Gowing E, Paterka M, Michel L, Dudvarski Stankovic N, Bicker F, Lemaître F, Prat A, et al: EGFL7 reduces CNS inflammation in mouse. Nature Commun. 9:8192018. View Article : Google Scholar : PubMed/NCBI |